Osteosarcoma - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 306 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Osteosarcoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Osteosarcoma - Pipeline Review, H1 2016', provides an overview of the Osteosarcoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
- The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Osteosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Osteosarcoma Overview 9
Therapeutics Development 10
Pipeline Products for Osteosarcoma - Overview 10
Pipeline Products for Osteosarcoma - Comparative Analysis 11
Osteosarcoma - Therapeutics under Development by Companies 12
Osteosarcoma - Therapeutics under Investigation by Universities/Institutes 15
Osteosarcoma - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Osteosarcoma - Products under Development by Companies 18
Osteosarcoma - Products under Investigation by Universities/Institutes 21
Osteosarcoma - Companies Involved in Therapeutics Development 22
Advaxis, Inc. 22
Amgen Inc. 23
Astellas Pharma Inc. 24
AVEO Pharmaceuticals, Inc. 25
Bayer AG 26
Bellicum Pharmaceuticals, Inc. 27
Cebiotex, S.L. 28
Celgene Corporation 29
Celldex Therapeutics, Inc. 30
CytRx Corporation 31
Eleison Pharmaceuticals LLC 32
EntreChem, S.L. 33
Exelixis, Inc. 34
Gradalis Inc. 35
Ipsen S.A. 36
Isofol Medical AB 37
Karyopharm Therapeutics, Inc. 38
Kolltan Pharmaceuticals, Inc. 39
MediaPharma s.r.l. 40
Merck & Co., Inc. 41
Merrimack Pharmaceuticals, Inc. 42
NanoSmart Pharmaceuticals, Inc. 43
Nanovalent Pharmaceuticals Inc. 44
NantKwest, Inc. 45
Netris Pharma S.A.S. 46
Novartis AG 47
Oncolys BioPharma Inc. 48
Oncomatryx Biopharma, S.L. 49
Recombio S.L 50
Shionogi & Co., Ltd. 51
Sigma-Tau S.p.A. 52
Sutro Biopharma, Inc. 53
Teijin Pharma Limited 54
Tesaro, Inc. 55
Tokalas, Inc. 56
United Therapeutics Corporation 57
Osteosarcoma - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Target 59
Assessment by Mechanism of Action 63
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
2-GES - Drug Profile 70
3BP-227 - Drug Profile 71
3D-QM - Drug Profile 72
3D-QMS - Drug Profile 73
ADXS-HER2 - Drug Profile 74
aldoxorubicin hydrochloride - Drug Profile 76
AM-7209 - Drug Profile 79
AU-101 - Drug Profile 80
AU-105 - Drug Profile 81
AV-203 - Drug Profile 82
cabozantinib s-malate - Drug Profile 83
CEB-01 - Drug Profile 87
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 88
Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 89
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 90
celyvir - Drug Profile 91
CGS-200 - Drug Profile 93
cisplatin SR - Drug Profile 94
dactinomycin next generation - Drug Profile 96
dinutuximab - Drug Profile 97
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 99
EC-8042 - Drug Profile 100
EC-8105 - Drug Profile 102
everolimus - Drug Profile 103
gemogenovatucel-T - Drug Profile 109
glembatumumab vedotin - Drug Profile 111
haNK Program - Drug Profile 113
irinotecan hydrochloride - Drug Profile 115
KIT-SG3227 - Drug Profile 118
ligerin - Drug Profile 120
linsitinib - Drug Profile 121
LLL-12 - Drug Profile 123
Modufolin - Drug Profile 124
Monoclonal Antibody Conjugate for Ewing Sarcoma - Drug Profile 126
Monoclonal Antibody for Osteosarcoma - Drug Profile 127
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 128
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 129
Monoclonal Antibody to Target GD2 for Osteosarcoma - Drug Profile 131
MPE-8.3 - Drug Profile 132
niraparib - Drug Profile 133
NP-137 - Drug Profile 135
NV-101 - Drug Profile 137
OBP-702 - Drug Profile 138
Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile 139
OMTX-503 - Drug Profile 140
OMTX-703 - Drug Profile 141
paclitaxel albumin bound - Drug Profile 142
pazopanib hydrochloride - Drug Profile 146
pembrolizumab - Drug Profile 152
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 162
racotumomab - Drug Profile 164
radium Ra 223 dichloride - Drug Profile 166
roneparstat - Drug Profile 169
RSF-101 - Drug Profile 170
S-588410 - Drug Profile 171
selinexor - Drug Profile 172
SEN-461 - Drug Profile 178
Small Molecules for Ewing Sarcoma - Drug Profile 179
Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile 180
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 181
SP-2509 - Drug Profile 182
SP-2528 - Drug Profile 184
SP-2577 - Drug Profile 185
ST-3595 - Drug Profile 186
T-2GES - Drug Profile 187
TK-216 - Drug Profile 188
Vaccine for Osteosarcoma - Drug Profile 189
YK-4279 - Drug Profile 190
Osteosarcoma - Recent Pipeline Updates 192
Osteosarcoma - Dormant Projects 290
Osteosarcoma - Discontinued Products 293
Osteosarcoma - Product Development Milestones 294
Featured News & Press Releases 294
Appendix 300
Methodology 300
Coverage 300
Secondary Research 300
Primary Research 300
Expert Panel Validation 300
Contact Us 300
Disclaimer 301

List of Tables
Number of Products under Development for Osteosarcoma, H1 2016 15
Number of Products under Development for Osteosarcoma - Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Number of Products under Development by Companies, H1 2016 (Contd..1) 18
Number of Products under Development by Companies, H1 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Development, H1 2016 22
Products under Development by Companies, H1 2016 23
Products under Development by Companies, H1 2016 (Contd..1) 24
Products under Development by Companies, H1 2016 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2016 26
Osteosarcoma - Pipeline by Advaxis, Inc., H1 2016 27
Osteosarcoma - Pipeline by Amgen Inc., H1 2016 28
Osteosarcoma - Pipeline by Astellas Pharma Inc., H1 2016 29
Osteosarcoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 30
Osteosarcoma - Pipeline by Bayer AG, H1 2016 31
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 32
Osteosarcoma - Pipeline by Cebiotex, S.L., H1 2016 33
Osteosarcoma - Pipeline by Celgene Corporation, H1 2016 34
Osteosarcoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 35
Osteosarcoma - Pipeline by CytRx Corporation, H1 2016 36
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H1 2016 37
Osteosarcoma - Pipeline by EntreChem, S.L., H1 2016 38
Osteosarcoma - Pipeline by Exelixis, Inc., H1 2016 39
Osteosarcoma - Pipeline by Gradalis Inc., H1 2016 40
Osteosarcoma - Pipeline by Ipsen S.A., H1 2016 41
Osteosarcoma - Pipeline by Isofol Medical AB, H1 2016 42
Osteosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 43
Osteosarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 44
Osteosarcoma - Pipeline by MediaPharma s.r.l., H1 2016 45
Osteosarcoma - Pipeline by Merck & Co., Inc., H1 2016 46
Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 47
Osteosarcoma - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016 48
Osteosarcoma - Pipeline by Nanovalent Pharmaceuticals Inc., H1 2016 49
Osteosarcoma - Pipeline by NantKwest, Inc., H1 2016 50
Osteosarcoma - Pipeline by Netris Pharma S.A.S., H1 2016 51
Osteosarcoma - Pipeline by Novartis AG, H1 2016 52
Osteosarcoma - Pipeline by Oncolys BioPharma Inc., H1 2016 53
Osteosarcoma - Pipeline by Oncomatryx Biopharma, S.L., H1 2016 54
Osteosarcoma - Pipeline by Recombio S.L, H1 2016 55
Osteosarcoma - Pipeline by Shionogi & Co., Ltd., H1 2016 56
Osteosarcoma - Pipeline by Sigma-Tau S.p.A., H1 2016 57
Osteosarcoma - Pipeline by Sutro Biopharma, Inc., H1 2016 58
Osteosarcoma - Pipeline by Teijin Pharma Limited, H1 2016 59
Osteosarcoma - Pipeline by Tesaro, Inc., H1 2016 60
Osteosarcoma - Pipeline by Tokalas, Inc., H1 2016 61
Osteosarcoma - Pipeline by United Therapeutics Corporation, H1 2016 62
Assessment by Monotherapy Products, H1 2016 63
Number of Products by Stage and Target, H1 2016 65
Number of Products by Stage and Mechanism of Action, H1 2016 69
Number of Products by Stage and Route of Administration, H1 2016 72
Number of Products by Stage and Molecule Type, H1 2016 74
Osteosarcoma Therapeutics - Recent Pipeline Updates, H1 2016 197
Osteosarcoma - Dormant Projects, H1 2016 295
Osteosarcoma - Dormant Projects (Contd..1), H1 2016 296
Osteosarcoma - Dormant Projects (Contd..2), H1 2016 297
Osteosarcoma - Discontinued Products, H1 2016 298